Racehorses are subjected to intensive training, often leading to musculoskeletal injuries that require management with non-steroidal anti-inflammatory drugs (NSAIDs). In Chile, the Consejo Nacional de la Hípica regulates equine sports and classifies NSAIDs, including phenylbutazone (PBZ), as doping agents. However, current pharmacokinetic data are limited, relying on small sample sizes that may affect their applicability. This study evaluated the elimination pharmacokinetics of IV-administered PBZ (4.4 mg/kg) in two groups of Thoroughbred racehorses: pre-competition horses (5 years). In the younger group, the elimination half-life was 3.69 h, C₀ was 17.58 mg/L, volume of distribution was 180 L, and clearance was 34.35 L/h, while in the older group, these values were 3.5 h, 19.62 mg/L, 108 L, and 27.95 L/h, respectively, with no significant differences between groups. These findings suggest that PBZ elimination kinetics are comparable across different age groups and provide relevant evidence for the formulation of regulatory policies in the field of equine sports medicine.